Literature DB >> 3478595

Novel chimaeric protein expressed in Philadelphia positive acute lymphoblastic leukaemia.

L C Walker1, T S Ganesan, S Dhut, B Gibbons, T A Lister, J Rothbard, B D Young.   

Abstract

Cytogenic changes are becoming increasingly important in understanding the pathogenesis of human malignancies. The t(9;22) (q34;q11) translocation is one of the most consistent and generates the Philadelphia chromosome (Ph1) (ref. 1) in chronic myeloid leukaemia (CML); it has also been observed in some acute lymphoblastic leukaemias (ALL) (ref. 2). In CML the breakpoints occur on chromosome 22 in the region designated bcr (ref. 3) and result in the expression of a bcr-abl fusion product of relative molecular mass (MT) 210,000 (210K) with associated in vitro tyrosine kinase activity (P210bcr-abl). In some cases of Ph1-positive ALL, a novel abl-related protein (P190all-abl) of 190K has been shown to have tyrosine kinase activity. In this report we demonstrate that the P190all-abl protein has a bcr determinant from the amino-terminal region, but is lacking a bcr determinant normally found in the P210bcr-abl near the bcr-abl junction. The chimaeric nature of the P190all-abl was confirmed by sequential immunoprecipitation with antisera against abl and bcr peptides.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3478595     DOI: 10.1038/329851a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  19 in total

1.  BCR/ABL induces multiple abnormalities of cytoskeletal function.

Authors:  R Salgia; J L Li; D S Ewaniuk; W Pear; E Pisick; S A Burky; T Ernst; M Sattler; L B Chen; J D Griffin
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

Review 2.  Molecular analysis of the Philadelphia chromosome.

Authors:  A Dobrovic; G B Peters; J H Ford
Journal:  Chromosoma       Date:  1991-09       Impact factor: 4.316

3.  The (6;9) chromosome translocation, associated with a specific subtype of acute nonlymphocytic leukemia, leads to aberrant transcription of a target gene on 9q34.

Authors:  M von Lindern; A Poustka; H Lerach; G Grosveld
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

Review 4.  Molecular analysis of Philadelphia chromosome positive leukaemias.

Authors:  B D Young
Journal:  Br J Cancer Suppl       Date:  1988-12

5.  Nucleotide sequence of both reciprocal translocation junction regions in a patient with Ph positive acute lymphoblastic leukaemia, with a breakpoint within the first intron of the BCR gene.

Authors:  M J van der Feltz; M K Shivji; P B Allen; N Heisterkamp; J Groffen; L M Wiedemann
Journal:  Nucleic Acids Res       Date:  1989-01-11       Impact factor: 16.971

6.  The first BCR gene intron contains breakpoints in Philadelphia chromosome positive leukemia.

Authors:  N Heisterkamp; E Knoppel; J Groffen
Journal:  Nucleic Acids Res       Date:  1988-11-11       Impact factor: 16.971

7.  Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3' half to different genes: characterization of the set gene.

Authors:  M von Lindern; S van Baal; J Wiegant; A Raap; A Hagemeijer; G Grosveld
Journal:  Mol Cell Biol       Date:  1992-08       Impact factor: 4.272

8.  The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA.

Authors:  M von Lindern; M Fornerod; S van Baal; M Jaegle; T de Wit; A Buijs; G Grosveld
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

9.  A 41-kilodalton protein is a potential substrate for the p210bcr-abl protein-tyrosine kinase in chronic myelogenous leukemia cells.

Authors:  E Freed; T Hunter
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

10.  Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene.

Authors:  M Kelliher; A Knott; J McLaughlin; O N Witte; N Rosenberg
Journal:  Mol Cell Biol       Date:  1991-09       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.